M3554

Phase 1Small molecule

EMD Serono Research & Development Institute, Inc.

M3554 is one of 31 small molecule programs targeting Advanced Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorRecruiting

Advanced Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

39 competitors in Advanced Solid Tumor

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 2

3 2

Taxol

Teva

Phase 1

4 3

Keytruda

Merck & Co.

Phase 1

3 4

Zytiga

Johnson & Johnson

Phase 1

1 5

Nubeqa

Bayer

Phase 1

1 6

Eloxatin

Teva

Phase 1

1 7

Abraxane

Bristol-Myers Squibb

Phase 1

1 8

Paraplatin

AAvyxa

Phase 1

3 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 10

Alimta

GGynecologic Oncology Group

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Advanced Solid Tumor

NCT06641908

Clinical

Trials by Indication[1]

Advanced Solid Tumor1 trial

A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of Anti-GD2 Antibody Drug Conjugate M3554 in Participants With Advanced Solid Tumors

Recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT06641908·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for M3554. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — M3554 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for M3554. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMD Serono Research & Development Institute, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EMD Serono Research & Development Institute, Inc.

M3554

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News